Non‐Responders to Biologic Disease Modifying Antirheumatic Treatment for Inflammatory Bowel Diseases
Svetla Gadzhanova, Elizabeth Roughead, Jasbir Arora (RSS) · 2025
Read Non‐Responders to Biologic Disease Modifying Antirheumatic Treatment for Inflammatory Bowel Diseases by Svetla Gadzhanova, Elizabeth Roughead, Jasbir Arora (RSS) (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12767434.txt.
Description
Svetla Gadzhanova and Elizabeth Roughead measure how often biologic drugs fail for bowel disease in Australia. The drugs calm the immune system in Crohn's disease and ulcerative colitis, two long-term bowel illnesses. The team used a ten percent sample of national drug records. They tracked adults who started a biologic in 2019 or 2020 for twelve months.
For Crohn's disease, fifteen percent stopped their first drug by week sixteen. Rates split by drug, with one drug lowest and another highest. For colitis, a quarter stopped by week sixteen, again with wide gaps by drug. The authors name which drugs held patients longest in each illness. Such rates can guide first choices and plans for switching drugs.
Catalog record
| CREATOR | Svetla Gadzhanova, Elizabeth Roughead, Jasbir Arora (RSS) |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |